Compare Cassava Sciences Inc (FLNA) vs NetEase Inc (NTES) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs NetEase Inc — how do they compare? Cassava Sciences Inc trades at $1.08 (market cap $53.14M), while NetEase Inc trades at $129.72 (market cap $82.39B). The key difference: NetEase Inc is far larger — about 1550.4× Cassava Sciences Inc's market cap, and NetEase Inc pays a 2.35% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | NTES | |
|---|---|---|
Market Cap | $53.14M | $82.39B |
Sector | Health | Media |
52-Week High | $4.64 | $159.34 |
52-Week Low | $1.09 | $109.26 |
Enterprise Value | -$33.43M | $58.86B |
Dividend Yield | — | 2.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
NetEase (NTES) trades at $128.39, down 2.31% on the day, with a bullish technical signal supported by moving averages. Fundamentally, the company shows strong profitability with a 29.84% net income margin and 22.12% ROE, though recent quarterly earnings have been mixed with two misses and one beat against expectations. Revenue growth continues at $112.63B for 2025, with improving profit margins reaching 29.97%. The stock trades at a P/E of 16.5 and P/S of 4.92, while analyst consensus remains strongly bullish with 82% buy ratings.
The outlook for NTES is positive due to strong fundamentals, international expansion, and attractive valuation, but risks include China regulatory exposure, competitive gaming market pressures, and recent earnings volatility. Wall Street sees 34.7% upside potential, though the stock faces headwinds from geopolitical tensions affecting Chinese tech stocks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About NetEase Inc
NetEase, which started on an internet portal service in 1997, is a leading online services provider in China. Its key services include online/mobile games, cloud music, media, advertising, email, live streaming, online education, and e-commerce. The company develops and operates some of the China's most popular PC client and mobile games, and it partners with global leading game developers, such as Blizzard Entertainment and Mojang (a Microsoft subsidiary).
Read more on NTES →
